You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Medtronic
Colorcon
Johnson and Johnson

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

VENETOCLAX - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for venetoclax and what is the scope of freedom to operate?

Venetoclax is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Venetoclax has one hundred and seventy-nine patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for VENETOCLAX
International Patents:179
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 75
Clinical Trials: 184
Patent Applications: 222
DailyMed Link:VENETOCLAX at DailyMed
Recent Clinical Trials for VENETOCLAX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aprea TherapeuticsPhase 1/Phase 2
Adaptive BiotechnologiesPhase 2
Technische Universität DresdenPhase 1/Phase 2

See all VENETOCLAX clinical trials

Pharmacology for VENETOCLAX
Drug ClassBCL-2 Inhibitor
Mechanism of ActionP-Glycoprotein Inhibitors
Physiological EffectIncreased Cellular Death
Paragraph IV (Patent) Challenges for VENETOCLAX
Tradename Dosage Ingredient NDA Submissiondate
VENCLEXTA TABLET;ORAL venetoclax 208573 2020-04-13

US Patents and Regulatory Information for VENETOCLAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No   Start Trial   Start Trial Y   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VENETOCLAX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2435432 1790021-8 Sweden   Start Trial PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138 20161207
2435432 C20170017 00231 Estonia   Start Trial PRODUCT NAME: VENETOKLAKS;REG NO/DATE: EU/1/16/1138 07.12.2016
2435432 PA2017015 Lithuania   Start Trial PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205
2435432 LUC00020 Luxembourg   Start Trial PRODUCT NAME: VENETOCLAX (VENCLYXTO); AUTHORISATION NUMBER AND DATE: EU/1/16/1138 20161207
2435432 CR 2017 00021 Denmark   Start Trial PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207
2435432 132017000054735 Italy   Start Trial PRODUCT NAME: VENETOCLAX(VENCLYXTO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1138, 20161207
2435432 122017000031 Germany   Start Trial PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161205
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Baxter
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.